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Abstract Although methemoglobinemia following alumi-
num phosphide (AlP) intoxication has been reported,
probable effect of blood level of methemoglobin (Met-Hb)
on outcome of AlP-poisoned patients has not yet been
investigated. This study aimed to evaluate blood levels of
methemoglobin in patients with AP intoxication and its
correlation with patient’s outcome. This prospective study
was carried out at the Loghman–Hakim poison hospital
from April 2009 to August 2009. All patients aged
>12 years who had ingested AlP and were admitted at the
hospital were enrolled in the study. Using the co-oximetry,
blood Met-Hb level was measured at the time of admission
and 24 h later if the patient survived. Forty-eight patients
with AlP intoxication including 24 males were evaluated.
Mean age of the patients was 25.5±9.5 years. There was
significant association between blood level of Met-Hb at
the time of admission and mortality (2.4%±7.1% in
survivors versus 15.2%±13.5% in non-survivors, P<
0.001). The same association was found at the 2nd day of
admission (2.9%±8.2% in survivors versus 26.5%±19.9%
in non-survivors, P=0.02). The present study found an
association between blood level of Met-Hb and mortality in
patients with AlP intoxication. Effect of administration of
vitamin C and methylene blue on outcome of patients with
AlP intoxication should be investigated in future studies.
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Introduction
Aluminum phosphide (AlP) is used frequently as fumigant
and rodenticide due to its low price, easy application, and
high efficacy [1]. In Iran, AlP is accessible as 3 g tablets
that are a combination of 56% AlP (total dose of 1,680 mg)
and 44% ammonium carbonate. After ingestion, AlP reacts
with water and hydrochloric acid in the stomach and
releases phosphine (PH3) which is a very toxic gas.
Although the exact mechanism has not been well defined,
PH3 is a mitochondrial toxin and interferes with enzyme
and protein synthesis [2–4]. It has been demonstrated that
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breakage of the mitochondrial oxidative phosphorylation
system can results in multiple organ dysfunction. Therefore,
therapeutic interventions maintaining enzyme activity may
improve clinical outcome of patients with AlP intoxication
[5]. It has been also suggested that AlP directly damage to
the vessels and red blood cells membrane [6].
Severe methemoglobinemia after AlP intoxication is a rare
event, and to the best of our knowledge, it has been reported
only in one case [7]. Exposure to chemicals that oxidize the
hemoglobin ferrous iron to the ferric form lead to production
of methemoglobin (Met-Hb) [7]. Decreased capacity of Met-
Hb to deliver enough oxygen to tissues may be another cause
of multiple organ failure following AlP intoxication. More-
over, intravenous hemolysis has been also reported due to
AlP intoxication which may have additional effect on
oxygen delivery impairment to the target tissues [8].
Role of Met-Hb in AlP poisoning has been also
investigated in an experimental study by Lall et al. [6].
They showed that blood levels of malonyldialdehyde
(MDA) and Met-Hb increase 10 and 30 min after ingestion
of AlP. They also suggested that administration of methy-
lene blue results in significant decline in both MDA and
Met-Hb levels. According to these facts, development of
Met-Hb following ingestion of AlP may have an important
effect on clinical outcome of patients with AlP intoxication;
however, to the best of our knowledge, there is no study
regarding blood level of Met-Hb after AlP intoxication. The
present study, therefore, aimed to evaluate blood level of
Met-Hb in patients with AlP intoxication and its correlation
with outcome of these patients.
Patients and Methods
This prospective study was carried out at the Loghman–
Hakim poison hospital from April 2009 to August 2009.
Ethical committee of human research of the Shaheed
Beheshti University of Medical Sciences approved the
protocol of study.
All patients older than 12 years who had ingested AlP
and were admitted at the intensive care unit of the
aforementioned hospital were enrolled into the study. For
each patient, demographics and number of ingested tablets
was recorded in addition to vital signs (systolic and
diastolic blood pressures, pulse and respiratory rates) at
the time of admission, 24 h later (2nd day of admission)
and 3rdday of admission if the patients survived. Moreover,
arterial blood gas was performed at the time of admission
and the 2nd day of hospitalization if the patient survived.
Using the co-oximetry [9, 10], Met-Hb was measured at the
time of admission and 24 h later if the patient survived.
Data were analyzed using SPSS 16 (SPSS Inc, Chicago,
Illinois, USA). Numerical data were expressed as mean ±
standard deviation. The Kolmogorov–Smirnov test was
used to test normal distribution of numerical variables.
Independent samples t test and Mann–Whitney test were
used to compare these variables.
Results
Forty-eight patients with AlP intoxication including 24
males were enrolled in the study. Mean age of the patients
was 25.5±9.5 years. The median number of ingested AlP
tablets was 1 (ranged from 0.25 to 10) which 29 cases
(60.4%) had ingested one tablet. Mean time interval from
ingestion of tablet to hospital admission was 82.5±
59.4 min (ranged from 10 to 240 min). A total of nine
deaths (18.8%) occurred in the studied population.
Dyspnean (n=21, 43.8%), nausea, vomiting and epigas-
tric pain (n=18, 37.5%) were the most frequent complaints
of the patients. At the time of admission, mean arterial level
of carbon dioxide and oxygen were 35.4±11.2 and 73.7±
36.4 mmHg, respectively. Compared to the survivors,
arterial pH was significantly lower in non-survivors at both
1st and 2nd day of admission. There was no significant
difference between mean arterial blood pressure in survi-
vors and non-survivors at the time of admission (P>0.05).
Table 1 demonstrates comparison of vital signs between
these two groups.
There was significant association between blood level of
Met-Hb at the time of admission and mortality and
survivors had a lower blood level of Met-Hb (2.4%±7.1%
versus 15.2%±13.5%, P<0.001). The same association was
found at the 2nd day of admission (2.9%±8.2% in
survivors versus 26.5%±19.9% in non-survivors, P=0.02).
Discussion
AlP intoxication is common in some countries such as
India and Iran due to easy access to this pesticide. Recurrent
Table 1 Comparison of measured clinical and lab parameters in
survived and non-survived patients
Survivors
(mean±SD)
Non-survivors
(mean±SD)
P value
MABP (mmHg) 75.1±11.5 66.7±12.2 >0.05
PR (beat/Min) 96.2±20.8 114.4±25.4 0.028
RR (number/Min) 17.3±8.6 7.5±11.6 0.037
Arterial pH at admission
(mmHg)
7.38±0.06 7.25±0.13 0.02
Arterial pH at 2nd day
of admission (mmHg)
7.39±0.07 7.20±0.16 0.008
RR respiratory rate, PR pulse rate, MABP mean arterial blood pressure
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vomiting and epigastric distress, cardiac arrhythmias, and
electrocardiographic abnormalities, acute respiratory fail-
ure, hepatic damage, bleeding diathesis, acute tubular
necrosis, and acute pericarditis are the main manifes-
tations of AlP intoxication [8]. Although it is not
common, intravascular hemolysis following AlP intoxica-
tion has been reported in the setting of glucose-
6-phosphate dehydrogenase (G-6-PD) deficiency [11, 12]
as well as individuals with normal level of G-6-PD [8]
which indicates oxidizing properties of AlP. In fact,
the agent can oxidize hemoglobin protein, precipitate
the oxidized protein as Heinz bodies, and finally
result in intravascular hemolysis [7]. Oxidizing property
of AlP may explain development of Met-Hb after AlP
intoxication as exposure to chemicals that oxidize the
hemoglobin ferrous iron to the ferric form can produce
Met-Hb [7].
Although methemoglobinemia due to AlP intoxication
has been reported only in one case [7], the present study
showed that there is a significant association between
blood level of Met-Hb and mortality in AlP intoxication
cases. Clinical manifestations of methemoglobinemia are
due to decreased O2-carrying capacity of hemoglobin and
consequent tissue hypoxia [13]. We believe that in
patients suffering from AlP intoxication, death occurs
mainly due to other more serious complications such as
hypotension and shock rather than methemoglobinemia.
However, methemoglobinemia via decreasing O2-carrying
capacity of hemoglobin worsens tissue hypoxia and
contribute to further deterioration of patient’s situation.
Methemoglobinemia should be suspected in the presence
of central cyanosis and low oxygen saturation (SpO2) on
pulse oximetry in the absence of more prevalent causes of
hypoxia such as cardiopulmonary dysfunctions [14].
Clinical manifestations of methemoglobinemia depend on
blood concentration of Met-Hb and vary from grayish
pigmentation of skin in low concentrations to death in
concentrations above 70% [15]. The definite diagnosis of
methemoglobinemia is made by using co-oximetry [15].
Methylene blue is the treatment of choice for methe-
moglobinemia and in both clinical and experimental
studies it has been shown that methylene blue decreases
Met-Hb concentration significantly [6, 14] and relieves
symptoms [7, 14]. However, in our center methylene blue
is not routinely administered in AlP intoxications. The
following protocol is employed for management of patients
with AlP intoxication: gastrointestinal lavage with potas-
sium permanganate (1:10000) and sodium bicarbonate,
administration of crystalloids, sodium bicarbonate, calcium
gluconate, magnesium sulfate, vasopressors, glucose-
insulin, and glucagon (if necessary), infusion of albumin,
intralipid, and starch (if indicated), and giving high
concentration of O2.
The lethal dose of AlP in human has not well
determined, and it has been reported that it can be varied
from 0.4 to 1.5 g [16, 17]. Interestingly, some authors have
suggested that there is no association between AlP-ingested
dose and mortality [1] which may be due to accidental and/
or intentional errors in reporting number of ingested tablets
by patients or their family members. In our study, 29 cases
(60.4%) had ingested one AlP tablet that delivers 1,680 mg
of AlP. [4] However, mortality rate in the present study was
lower than previous reports [1, 4, 17]. In the study by
Shadnia and colleagues, death occurred in 31% of the
studied patients [1] and in the study by Singh et al.
mortality rate was as high as 59% [17]. Perhaps, it can be
explained by relatively short interval from intoxication to
hospital admission in our study. In the study by Shadnia et
al., the mean time to hospital admission was 4.2 h [1] which
is considerably longer than the present study (82.5 min).
Regarding the sex and age distribution of AlP intoxica-
tion, our findings were consistent with previous reports
which demonstrated AlP intoxication occurs almost equally
in both sexes and mean age of the patients is between 25
and 30 years[1, 4].
Possible errors in taking history from patients to their
family members due to giving accidental and/or intentional
incorrect response are a potential limitation of this study.
In conclusion, the present study revealed that there is a
significant association between blood level of Met-Hb and
mortality in patients with AlP intoxication. Effect of
administration of vitamin C and methylene blue on
outcome of patients with AlP intoxication should be
investigated in future studies.
Acknowledgment The authors are grateful to Farzan Institute of
Education and Technology for support and institutional facilities.
References
1. Shadnia S, Sasanian G, Allami P et al (2009) A retrospective 7-
years study of aluminum phosphide poisoning in Tehran:
opportunities for prevention. Hum Exp Toxicol 28:209–213
2. Gupta S, Ahlawat SK (1995) Aluminum phosphide poisoning—a
review. J Toxicol Clin Toxicol 33:19–24
3. Burgess JL, Morrissey B, Keifer MC, Robertson WO (2000)
Fumigant-related illnesses: Washington State’s five-year experi-
ence. J Toxicol Clin Toxicol 38:7–14
4. Mehrpour O, Alfred S, Shadnia S et al (2008) Hyperglycemia in
acute aluminum phosphide poisoning as a potential prognostic
factor. Hum Exp Toxicol 27:591–595
5. Singh S, Bhalla A, Verma SK, Kaur A, Gill K (2006)
Cytochrome-c oxidase inhibition in 26 aluminum phosphide
poisoned patients. Clin Toxicol (Phila) 44:155–158
6. Lall SB, Peshin SS, Mitra S (2000) Methemoglobinemia in
aluminium phosphide poisoning in rats. Indian J Exp Biol 38:95–97
7. Lakshmi B (2002) Methemoglobinemia with aluminum phosphide
poisoning. Am J Emerg Med 20:130–132
42 J. Med. Toxicol. (2011) 7:40–43
8. Aggarwal P, Handa R, Wig N, Biswas A, Saxena R, Wali JP
(1999) Intravascular hemolysis in aluminium phosphide poison-
ing. Am J Emerg Med 17:488–489
9. Barker SJ, Curry J, Redford D, Morgan S (2006) Measurement of
carboxyhemoglobin and methemoglobin by pulse oximetry: a
human volunteer study. Anesthesiology 105:892–897
10. Maurtua MA, Emmerling L, Ebrahim Z (2004) Anesthetic
management of a patient with congenital methemoglobinemia. J
Clin Anesth 16:455–457
11. Sood AK, Mahajan A, Dua A (1997) Intravascular haemolysis
after aluminium phosphide ingestion. J R Soc Med 90:47–48
12. Srinivas R, Agarwal R, Jairam A, Sakhuja V (2007) Intravascular
haemolysis due to glucose-6-phosphate dehydrogenase deficiency
in a patient with aluminium phosphide poisoning. Emerg Med J
24:67–68
13. Chui JS, Poon WT, Chan KC, Chan AY, Buckley TA (2005)
Nitrite-induced methaemoglobinaemia—aetiology, diagnosis and
treatment. Anaesthesia 60:496–500
14. Baraka AS, Ayoub CM, Yazbeck-Karam V et al (2005) Prophy-
lactic methylene blue in a patient with congenital methemoglobi-
nemia. Can J Anaesth 52:258–261
15. do Nascimento TS, Pereira RO, de Mello HL, Costa J (2008)
Methemoglobinemia: from diagnosis to treatment. Rev Bras
Anestesiol 58:657–664
16. Avasthi R, Sharma R (1994) Aluminium phosphide poisoning
and magnesium sulphate therapy. J Assoc Physicians India
42:670
17. Singh S, Singh D, Wig N, Jit I, Sharma BK (1996) Aluminum
phosphide ingestion—a clinico-pathologic study. J Toxicol Clin
Toxicol 34:703–706
J. Med. Toxicol. (2011) 7:40–43 43
